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Background: Artificial neural network (ANN)-based bone scan index (BSI), a marker of the amount of bone
metastasis, has been shown to enhance diagnostic accuracy and reproducibility but is potentially affected by
training databases. The aims of this study were to revise the software using a large number of Japanese databases
and to validate its diagnostic accuracy compared with the original Swedish training database.
Methods: The BSI was calculated with EXINIbone (EB; EXINI Diagnostics) using the Swedish training database
(n = 789). The software using Japanese training databases from a single institution (BONENAVI version 1, BN1,
n = 904) and the revised version from nine institutions (version 2, BN2, n = 1,532) were compared. The diagnostic
accuracy was validated with another 503 multi-center bone scans including patients with prostate (n = 207), breast
(n = 166), and other cancer types. The ANN value (probability of abnormality) and BSI were calculated. Receiver
operating characteristic (ROC) and net reclassification improvement (NRI) analyses were performed.
Results: The ROC analysis based on the ANN value showed significant improvement from EB to BN1 and BN2.
In men (n = 296), the area under the curve (AUC) was 0.877 for EB, 0.912 for BN1 (p = not significant (ns) vs. EB) and
0.934 for BN2 (p = 0.007 vs. EB). In women (n = 207), the AUC was 0.831 for EB, 0.910 for BN1 (p = 0.016 vs. EB), and
0.932 for BN2 (p < 0.0001 vs. EB). The optimum sensitivity and specificity based on BN2 was 90% and 84% for men
and 93% and 85% for women. In patients with prostate cancer, the AUC was equally high with EB, BN1, and BN2
(0.939, 0.949, and 0.957, p = ns). In patients with breast cancer, the AUC was improved from EB (0.847) to BN1
(0.910, p = ns) and BN2 (0.924, p = 0.039). The NRI using ANN between EB and BN1 was 17.7% (p = 0.0042), and that
between EB and BN2 was 29.6% (p < 0.0001). With respect to BSI, the NRI analysis showed downward reclassification
with total NRI of 31.9% ( p < 0.0001).
Conclusion: In the software for calculating BSI, the multi-institutional database significantly improved identification
of bone metastasis compared with the original database, indicating the importance of a sufficient number of
training databases including various types of cancers.
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Bone scintigraphy has been accepted as a means to iden-
tify bone metastases associated with various types of
cancer. Even after the advent of single-photon emission
computed tomography combined with X-ray computed
tomography, whole-body bone imaging is a standard
method to survey the existence and extent of bone me-
tastasis. Moreover, although bone scan interpretation
may be performed on visual interpretation of whole-
body images, an appropriate quantitative approach has
been expected. While initial detection of bone metasta-
ses is important, quantification of progress of metastasis
that results in patients’ disability, pain, pathological frac-
tures, and mortality would be also beneficial [1,2]. How-
ever, there had been no definite imaging method that
reflected metastatic disease burden and treatment effect
before the advent of bone scan index (BSI) proposed at
Memorial Sloan-Kettering Cancer Center [3].
The BSI was developed as a marker of the spread for
bone metastasis, which is a fraction of bones involved by
a tumor and which realizes the regional distribution of
the lesions [4]. The software program for calculating BSI
using the neural network system has also been devel-
oped using whole-body images with a Swedish database
[5]. They successfully applied automatic segmentation of
the skeletal regions and automatic detection and feature
extraction of hot spots using the neural network system.
However, the diagnostic accuracy is potentially influ-
enced by training databases. Whether the same database
can be used universally in any study population is yet to
be determined. The initial version using a Japanese data-
base showed promising results with a revised database,
but it was based on a single-center database [6,7].
The aims of this study were to create a multi-center
Japanese database based on a large number of subjects
with and without definite bone metastasis and to test
the diagnostic accuracy compared with the original
European database. In addition, to understand the char-
acteristics of diagnostic accuracy based on the newTable 1 Demographics of European and Japanese databases
EB BN1
N 789 904
Age (years) 66 ± 12 64 ± 12
Male, N (%) 508 (64) 457 (51)
Bone metastases, N (%) 262 (33) 141 (16)
Types of cancer
Prostate, N (%) 425 (54) 267 (30)
Breast, N (%) 217 (28) 383 (42)
Others, N (%) 147 (19) 254 (28)




The new multi-center training database used in the de-
velopment of BONENAVI version 2 (BN2) comprised
1,532 patients from nine Japanese hospitals (Table 1).
The average age was 68 ± 10 (range 20 to 99) years for
males and 59 ± 12 (range 26 to 91) years for females. A
total of 42% of the patients had bone metastasis, with
the underlying cancer being prostate cancer in 29%,
breast cancer in 41%, and other cancers in 30% of the
cases. In all hospitals, radiology and/or nuclear medicine
specialists made the definitive diagnoses. Every hot spot
was classified as metastasis or not, based on information
from multiple modalities including X-ray computed
tomography (CT), magnetic resonance imaging, positron
emission computed tomography, and serial bone scan
follow-up studies. All patients had X-ray CT studies, and
1,434 (94%) patients had two or more bone scans.
Blood sampling including biochemical bone and tumor
markers and the patient clinical courses were also used
to reach the gold standard classification. Hot spots most
likely due to degenerative disease or arthritis, for ex-
ample, in the vertebrae and shoulder joints, were judged
as non-metastatic.
The performance of BN2 was compared to that of
EXINIbone (EB; version 1.3, EXINI Diagnostics AB,
Lund, Sweden) and the first version of BONENAVI
(BN1; collaboration between EXINI Diagnostics AB and
FUJIFILM RI Pharma, Co. Ltd, Tokyo, Japan). The train-
ing database of EB comprised 789 bone scans from a
single Swedish hospital [9], and that of BN1 comprised
904 bone scans from a single Japanese hospital [7]. The
demographics of the patients from the different training
databases are shown in Table 1.
A validation group, used to test the performance of EB,
BN1, and BN2, was developed as a second multi-centerand validation groups
BN2 Validation group
All Male Female
1,532 503 296 207
64 ±12 65 ± 11 68 ±9 59 ± 12
790 (52) 296 (59) - -
638 (42) 169 (34) 96 (32) 73 (35)
451 (29) 207 (41) 207 (70) -
624 (41) 166 (33) - 166 (80)
457 (30) 130 (26) 89 (30) 41 (20)
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hospitals that participated in the BN2 training database
(Table 1). The classification criteria regarding meta-
static diseases were the same as in BN2. The underlying
malignancies other than breast cancer and prostate cancer
(n = 130) were lung cancer (n = 49), renal cancer (n = 17),
esophageal cancer (n = 8), gastric cancer (n = 6), thyroid
cancer (n = 5), pancreatic cancer (n = 5), and other types
of malignancy (n = 4 or less for each type).
To accumulate the scintigraphic images for the data-
bases, even though the DICOM data were anonymized,
approval of the institutional review board or ethical
committee was obtained in all institutions. All the data
were accumulated retrospectively. The review boards
waived the written informed consent from each patient.
Whole-body bone scan
Whole-body anterior and posterior images were used for
the analysis. A standard dose of 555 to 740 MBq of
99mTc-methylene diphosphonate (MDP; FUJIFILM RI
Pharma, Co. Ltd, Tokyo, Japan) was injected and imaged
3 h (range 2.5 to 5.5 h) later. The matrix size was 256 ×
1,024. Energy peak was centered at 140 keV with 15% to
20% windows.
Automated bone scan analysis
The automated method for analysis of anterior and pos-
terior whole-body bone scan images has been described
previously [9]. Segmentation of the skeleton was per-
formed by fitting an atlas to the patient skeleton using
Morphon registration for non-rigid image registration.
The atlases were based on 10 normal bone scans from
European patients for EB and 23 normal bone scans
from Japanese patients for BN1, whereas gender-specific
atlases were developed for BN2 using normal bone scans
from 25 male and 25 female Japanese patients. Regions
inside the delineated skeleton with intensities exceeding
a threshold were defined as hot spots. This threshold var-
ied over different parts of the skeleton and was propor-
tional to the overall intensities found in a neighborhood
surrounding each hot spot. This made the algorithm
equally sensitive to hot spots in low-intensity regions
such as the ribs and high-intensity regions such as the
lumbar spine. Each individual hot spot was classified as
metastasis or not by an artificial neural network (ANN).
Separate ANNs were used for each anatomical region,
e.g., skull, spine, ribs, pelvis, and femur, and the different
ANNs were used as input for specific sets of variables such
as size, shape, intensity, and localization of the hot spot.
The training databases for EB, BN1, and BN2 were different
as described above, and gender-specific ANNs were devel-
oped for BN2. The training of the ANNs was performed
using customized software at EXINI Diagnostics. The skel-
etal involvement of each hot spot was calculated as thepercentage of the total skeleton, and the BSI was calculated
as the sum of the skeletal involvement of all hot spots clas-
sified as metastases by the ANNs.
Statistical analysis
All the data were expressed as an average and standard
deviation. Contingency table analysis was performed to
compare values in two groups. The receiver operating
characteristic (ROC) analysis was performed and the
area under the curve (AUC) was calculated. An optimal
cutoff for the sensitivity and specificity could be calcu-
lated as the highest value of sensitivity − (1 − specificity).
The net reclassification improvement (NRI) analysis for
identifying bone metastasis was performed using four
ANN groups of 0 to 0.24, 0.25 to 0.49, 0.50 to 0.74, and
0.75 to 1.00 [8]. In order to evaluate the effect of the
software revisions on BSI, the NRI analysis was also per-
formed using four BSI groups of <0.1, 0.1 to 0.99, 1 to
4.99, and ≥5. P values <5% were considered significant.
Results
ROC and optimal sensitivity and specificity
Diagnostic accuracy based on ANN was examined using
ROC analysis (Figure 1). Since the databases were made
separately for men and women, the ROC AUC based on
ANN was calculated in each gender. In men (n = 296),
the AUC was 0.877, 0.912, and 0.934 for EB, BN1 (p =
not significant (ns) vs. EB), and BN2 (p = 0.007 vs. EB),
respectively. The sensitivity was determined as 83% for
EB, 88% for BN1 (p = ns vs. EB), and 90% for BN2 (p =
ns vs. EB), whereas specificity was determined as 69%
for EB, 83% for BN1 (p = 0.001 vs. EB), and 84% for BN2
(p = 0.001 vs. EB). In women (n = 207), the AUC was
0.831, 0.910, and 0.932 for EB, BN1 (p = 0.016 vs. EB),
and BN2 (p < 0.001 vs. EB), respectively. The sensitivity
was determined as 90% for EB, 81% for BN1 (p = 0.167
vs. EB), and 93% for BN2 (p = 0.774 vs. EB), whereas the
specificity was determined as 51% for EB, 87% for BN1
(p < 0.001 vs. EB), and 85% for BN2 (p < 0.001 vs. EB).
Figure 2 shows differences in ROC curves depending
on cancer types. When ANN was used to discriminate
metastatic patients with both genders combined, the
ROC AUC was 0.858 for EB, 0.910 for BN1 (p = 0.067
vs. EB), and 0.932 for BN2 (p < 0.0001 vs. EB). In pa-
tients with prostate cancer, the ROC AUC was not im-
proved from EB (0.939), BN1 (0.949), to BN2 (0.957). In
patients with breast cancer, however, AUC was improved
from EB (0.847) to BN1 (0.910, p = ns) and EB to BN2
(0.924, p = 0.039). In patients with other cancers, AUC
was significantly improved from EB (0.770) to BN1
(0.861, p = 0.023) and EB to BN2 (0.914, p < 0.0001).
When NRI analys is was performed between EB and BN2,
net gain in reclassification proportion in patients with metas-
tasis (n= 169) was 3.6% (p=ns), whereas it was −26.0%
Figure 1 Diagnostic accuracy based on ANN assessed by ROC analysis for EB, BN1, and BN2. Squares in graphs indicate sensitivity and
specificity adjusted for optimal balance of ANN, while tangential lines indicate the highest sensitivity − (1 − specificity).
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(Table 2). Total NRI was 29.6% and was highly signifi-
cant (p < 0.0001). The NRI from EB to BN1 was 17.7%
(p = 0.0042) with net gains of −5.3% (p = ns) and −23.1%
(p < 0.0001) in patients with and without metastasis,
respectively. The NRI from BN1 to BN2 was 10.4%
(p = 0.064) with net gains of 10.1% (p = 0.020) and −0.3%
(p = ns) in patients with and without metastasis,
respectively.
NRI analysis was also performed to evaluate the effect
of revision on BSI (Table 3). When EB and BN2 were
compared in patients with metastasis, the net gain in re-
classification proportion in patients with metastasis
was −40.8% (p < 0.0001). In patients without metastasis,
the net gain was −72.8% (p < 0.0001). The total NRI was
31.9% and was highly significant (p < 0.0001).
Figure 3 shows a patient with prostate cancer with
bone metastasis and a patient with breast cancer without
bone metastasis. In the patient with prostate cancer, the
metastatic lesions were correctly identified by BN2. The
breast cancer patient showed a high BSI with EB and a
lower BSI in BN1. The BSI was correctly diagnosed as 0
with BN2.Discussion
This study was performed as a multi-center project to
establish a software program by incorporating a database
that includes large number of patients with bone metas-
tasis from various cancer types. While the software
based on a Japanese single-center database improved the
diagnostic accuracy compared with the software based
on the original European database, the multi-center
database including 1,532 patients further enhanced the
diagnostic accuracy. The large training database also
made it possible to use gender-specific analysis in BN2.
In addition to the diagnostic use of the software, BSI
provides a quantitative measure that reflects the tumor
burden expressed as a percentage of total body skeletal
mass. The initial study started at Memorial Sloan-
Kettering Cancer Center in patients with prostate cancer
and showed good reproducibility and a parallel change
with prostate-specific antigen [3,4]. BSI has been proved
to contain prognostic information in addition to that of
conventional prognostic markers such as clinical T stage,
Gleason score, and prostate-specific antigen, and it has
therefore drawn the attention of oncologists and urolo-
gists [10]. When prostate cancer patients were stratified
Figure 2 Diagnostic accuracy based on ANN evaluated by ROC analysis for EB (red), BN1 (green), and BN2 (blue). The ROCs are
compared in the groups of prostate cancer, breast cancer, and other cancers.
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groups, significant differences in survival rate were dem-
onstrated [11-13]. On-treatment changes in BSI could
be a good response indicator rather than prostate-
specific antigen alone in patients with castration-
resistant metastatic prostate cancer.
The quantification of bone scans became practical by
the use of a computer-aided diagnosis system withANN, since the quality of visual bone scan interpretation
varied according to readers’ experiences [14]. When the
segmentation of the skeletons, hot spot detection, evalu-
ation of the characteristics of hot areas, and summed
quantitative indexes were available with an automatic
method, the reproducibility could be enhanced [5,15]. In
a study using EB, a close correlation was demonstrated
between manual and automated BSI measurements, and
Table 2 Net reclassification improvement analyses between EB and BN2 based on ANN groups
EB BN2
0 to 0.24 0.25 to 0.49 0.50 to 0.74 0.75 to 1.00 Total
Metastasis (n = 169): net gain in reclassification
proportion = 3.6%, p = 0.38
0 to 0.24 1 3 3 3 10
0.6% 1.8% 1.8% 1.8%
0.25 to 0.49 2 2 4 5 13
1.2% 1.2% 2.4% 3.0%
0.50 to 0.74 2 1 5 8 16
1.2% 0.6% 3.0% 4.7%
0.75 to 1.00 1 3 11 115 130
0.6% 1.8% 6.5% 68.0%
Total 6 9 23 131 169
No metastasis (n = 334): net gain in reclassification
proportion = −26.0%, p < 0.0001
0 to 0.24 96 31 14 4 145
28.7% 9.3% 4.2% 1.2%
0.25 to 0.49 41 14 5 2 62
12.3% 4.2% 1.5% 0.6%
0.50 to 0.74 34 19 9 5 67
10.2% 5.7% 2.7% 1.5%
0.75 to 1.00 35 11 8 6 60
10.5% 3.3% 2.4% 1.8%
Total 206 75 36 17 334
Total NRI = 29.6%, p < 0.0001.
Table 3 Net reclassification improvement analyses between EB and BN2 based on BSI groups
EB BN2
<0.1 0.1 to 1 1 to 5 >5 Total
Metastasis (n = 169): net gain in reclassification
proportion = −40.8%, p < 0.0001
<0.1 3 0 0 0 3
1.8% 0.0% 0.0% 0.0%
0.1 to 1 6 28 0 0 34
3.6% 16.6% 0.0% 0.0%
1 to 5 4 48 40 0 92
2.4% 28.4% 23.7% 0.0%
>5 0 1 10 29 40
0.0% 0.6% 5.9% 17.2%
Total 13 77 50 29 169
No metastasis (n = 334) net gain in reclassification
proportion = −72.8%, p < 0.0001
<0.1 43 4 0 0 47
25.4% 2.4% 0.0% 0.0%
0.1 to 1 129 31 0 0 160
76.3% 18.3% 0.0% 0.0%
1 to 5 63 38 9 0 110
37.3% 22.5% 5.3% 0.0%
>5 7 7 3 0 17
4.1% 4.1% 1.8% 0.0%
Total 242 80 12 0 334
Total NRI = 31.9%, p < 0.0001.
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Figure 3 A 69-year-old man with prostate cancer (A) and a 53-year-old woman with breast cancer (B). The patient with prostate cancer
had multiple metastases that were correctly identified by BN2, and the BSI was increased with BN2 compared with EB. The patient with breast
cancer did not have metastasis, and both ANN and BSI were reduced by the revised versions with Japanese training databases. Red hot spots
denote high-risk lesions, namely high probability of metastases, whereas blue hot spots denote low-risk lesions.
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Owing to simple application, BSI could be incorporated
into clinical practice, while patients were diagnosed,
treated, and followed up on.
Training databases are essential for a neural network
system to diagnose bone metastases. In this study, we used
only Japanese patients with definite diagnosis for the exist-
ence of bone metastasis. In addition to patient-based diag-
nostic accuracy, all the hot areas were confirmed by other
imaging modalities and/or follow-up bone scans. Since the
BN1 included only 141 (16%) patients with bone metastases
from one hospital, it was increased to 638 (42%) patients
from nine hospitals. The number of hot spots in ribs, for
example, was increased from 2,303 (metastasis 50%) in
BN1 to 3,294 (metastasis 43%) in BN2, which contributed
to enhancing the learning volumes. When it is utilized in a
number of hospitals, the multi-center database judged by
multiple experts would be beneficial for enhancing diagnos-
tic accuracy in computer learning.
The larger collection of databases including various
cancer types is essential for obtaining appropriate BSI
values. When we used the EB on Japanese patients for
the first time, hot spots indicating high probability of ab-
normality were frequently noticed in the skull, shoulder
joints, and lumbar vertebrae. These regions included dif-
fuse metabolic accumulation in the skull of female pa-
tients and degenerative changes in the vertebrae and
joints. About half (n = 425) of the Swedish database was
from prostate cancer and 28% (n = 217) from breast can-
cer. In contrast, the Japanese databases for BN2 included
29% (n = 451) from prostate cancer, 41% (n = 624) frombreast cancer, and 30% (n = 457) from other cancer
types. The BN2 databases, therefore, included various
cancer types and were closer to the usual clinical envir-
onment. From the viewpoint of Japanese population-
specific databases, not only the physical stature but also
the incidence of degenerative or deformative bone
changes might differ between Swedish and Japanese sub-
jects. When EB and BN1 were compared, NRI analysis
with ANN showed that BN1 increased negative cases in
patients without metastasis, indicating significantly de-
creased false-positive cases. BN2 further adjusted the
diagnostic accuracy and reclassified the metastatic le-
sions into the higher ANN groups. With respect to the
influence of revisions on BSI, the NRI analysis showed
that reclassification was downward in both metastatic
and non-metastatic groups. However, reclassification of
non-metastatic patients into the lower risk BSI seemed
to have meaning, and total net reclassification was im-
proved in one third of the patients. The final effect of re-
vision on predicting prognosis should be confirmed in
future follow-up studies.
Notable effects of training databases differ among
prostate, breast, and other cancers. The differences
among cancer types seemed to be related to osteoblastic
and osteolytic activity of the bone metastases and their
imbalance in regulation [16]. Quantitative measurement
of bone metastasis or BSI has most widely been used in
patients with prostate cancer [9,10,12,17,18]. Prostate
cancer shows typical osteoblastic metastasis based on
radiological findings, though it is also associated with
osteoclastic process and bone resorption. The bone scan
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and even the so-called superscan in extreme situations.
Detecting all metastatic hot areas is important when de-
manding an overview of the whole amount of metastasis
in prostate cancer. Therefore, the diagnostic accuracy in
identifying bone metastasis was high even with EB, and
further improvement by BN1 and BN2 was not achieved.
In contrast, breast cancer commonly metastasizes to
bones and destroys its structure, which causes both
osteolytic and osteoblastic appearance in bones. The
bone scan might show relatively mild activity or even
cold areas in the pure osteolytic lesions. Higher fractions
of breast and other cancer types in BN2 as compared
with EB were also noted, namely, non-prostate cancer,
46% (n = 364) for EB, 70% (n = 637) for BN1, and 71%
(n = 1081) for BN2 (Table 1). To enhance the diagnostic
accuracy in breast cancer metastasis, decreasing false-
positive hot spots had practically important meaning,
and it explained why the diagnostic improvement was
obtained in BN1 and BN2 as compared with EB.
Limitations
The detection of metastasis was based on the hot areas,
and cold lesions were not included for training the ANN
system. However, since most of the diagnosis of the bone
metastasis was made by the accumulation of 99mTc-MDP,
the utility of BSI would not be substantially changed.
Although database training was performed using all
subjects, specific cancer type-based training, for example,
prostate cancer-specific and breast cancer-specific train-
ing databases, could be applied. This process requires
considerable time for separate training and will be studied
in future works. Finally, when the NRI analysis is performed
based on skeletal-related events, instead of diagnosis of
metastases, true values of BSI will be confirmed in the
future.
Even when we consider the possibility of 18 F NaF
positron emission computed tomography in the future, a
similar approach using ANN and new training databases
might be an interesting project. What kinds of algorithm
of ANN system are appropriate for tomographic images
and/or maximum intensity projection images should be
investigated.
Conclusion
The Japanese multi-center database significantly im-
proved the diagnostic accuracy, showing AUC of 0.93 in
both genders with ANN. The improvement from EB to
BN1 to BN2 was particularly high in patients with breast
cancer and other cancer types, while the diagnostic ac-
curacy was equally high in patients with prostate cancer.
Reclassification analysis showed that the main improve-
ment was the decrease of false-positive results and that
non-metastatic patients were reclassified into lower BSIgroups. A large number of training databases including
various cancer types were effective in improving the
diagnostic accuracy.
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